Christian Harding | CSO & Co-founder
Omniose

I am the founder of Omniose (formerly VaxNewMo) dating back to 2016 when I left my postdoctoral fellowship to lead company formation and build out its laboratory infrastructure. Since then, I have established multiple R&D programs developing polysaccharide-protein conjugate vaccines targeting bacterial pathogens with unmet medical need. I am the main innovator and driver for all Omniose R&D activities, including development of its proprietary bioconjugation platform. Currently, I lead a team of 20 scientists focusing on bacterial vaccine development. Over the last eight years I have refined Omniose’s bioconjugation technology for use in developing bioconjugate vaccines against multiple bacterial targets, including, Group B Streptococcus and Klebsiella pneumoniae. I have devised and solely authored seven awarded SBIR/STTR grants totaling more than $15M in non-dilutive funding, fueling Omniose’s R&D pipeline and company growth. The refinements and improvements to the Omniose bioconjugation platform developed under my leadership culminated in a three year exclusive, strategic research collaboration with AstraZeneca starting in Q1 of 2024. I am an inventor on 10 Omniose (VaxNewMo) and AstraZeneca patents covering a broad range of platform applications and compositions of matter relating to the Omniose polysaccharide protein bioconjugation technology. In addition to my CSO responsibilities, I have been an active Board Member for nine years. I have co-authored >25 peer-reviewed manuscripts in distinguished journals.